Novavax (NVAX) may be the COVID-19 vaccine winner
Novavax (NVAX) opened at $18.25, which means the stock is down 1.20% from yesterday’s closing price of 18.06. Today, the company has a high of $18.70 and a low of $17.74. The company has a market cap of $1.03 billion with a 52-week high of $26.34 and a 52-week low of $3.54.
What about the future for Novavax?
The high forecast for Novavax is 33.00 while the low is 19.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Novavax has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future.. Based on this information NVAX seems to be a safe buy.
Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm’s vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.